Show simple item record

dc.contributor.authorKamarajah, Sivesh K
dc.contributor.authorMarkar, Sheraz R
dc.contributor.authorPhillips, Alexander W
dc.contributor.authorKunene, Victoria
dc.contributor.authorFackrell, David
dc.contributor.authorSalti, George I
dc.contributor.authorDahdaleh, Fadi S
dc.contributor.authorGriffiths, Ewen A
dc.date.accessioned2024-01-02T16:20:09Z
dc.date.available2024-01-02T16:20:09Z
dc.date.issued2022-06-08
dc.identifier.citationKamarajah SK, Markar SR, Phillips AW, Kunene V, Fackrell D, Salti GI, Dahdaleh FS, Griffiths EA. Survival benefit of adjuvant chemotherapy following neoadjuvant therapy and oesophagectomy in oesophageal adenocarcinoma. Eur J Surg Oncol. 2022 Sep;48(9):1980-1987. doi: 10.1016/j.ejso.2022.05.014. Epub 2022 Jun 8en_US
dc.identifier.issn0748-7983
dc.identifier.eissn1532-2157
dc.identifier.doi10.1016/j.ejso.2022.05.014
dc.identifier.pmid35718676
dc.identifier.urihttp://hdl.handle.net/20.500.14200/3308
dc.description.abstractBackground: The evidence assessing the additional benefits of adjuvant chemotherapy (AC) following neoadjuvant therapy (NAT; i.e. chemotherapy or chemoradiotherapy) and oesophagectomy for oesophageal adenocarcinoma (EAC) are limited. This study aimed to determine whether AC improves long-term survival in patients receiving NAT and oesophagectomy. Methods: Patients receiving oesophagectomy for EAC following NAT from 2004 to 2016 were identified from the National Cancer Data Base (NCDB). To account for immortality bias, patients with survival ≤3 months were excluded to account for immortality bias. Propensity score matching (PSM) and Cox regression was performed to account for selection bias and analyze impact of AC on overall survival. Results: Overall, 12,972 (91%) did not receive AC and 1,255 (9%) received AC. After PSM there were 2,485 who did not receive AC and 1,254 who did. After matching, AC was associated with improved survival (median: 38.5 vs 32.3 months, p < 0.001), which remained after multivariable adjustment (HR: 0.78, CI95%: 0.71-0.87). On multivariable interaction analyses, this benefit persisted in subgroup analysis for nodal status: N0 (HR: 0.85, CI95%: 0.69-0.96), N1 (HR: 0.66, CI95%: 0.56-0.78), N2/3 (HR: 0.80, CI95%: 0.66-0.97) and margin status: R0 (HR: 0.77, CI95%: 0.69-0.86), R1 (HR: 0.60, CI95%: 0.43-0.85). Further, patients with stable disease following NAT (HR: 0.60, CI95%: 0.59-0.80) or downstaged (HR: 0.80, CI95%: 0.68-0.95) disease had significant survival benefit after AC, but not patients with upstaged disease. Conclusion: AC following NAT and oesophagectomy is associated with improved survival, even in node-negative and margin-negative disease. NAT response may be crucial in identifying patients who will benefit maximally from AC, and thus future research should be focused on identifying molecular phenotype of tumours that respond to chemotherapy to improve outcomes.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttp://www.sciencedirect.com/science/journal/07487983en_US
dc.rightsCopyright © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
dc.subjectSurgeryen_US
dc.subjectOncology. Pathology.en_US
dc.subjectGeneticsen_US
dc.titleSurvival benefit of adjuvant chemotherapy following neoadjuvant therapy and oesophagectomy in oesophageal adenocarcinoma.en_US
dc.typeArticle
dc.source.journaltitleEuropean Journal of Surgical Oncology
dc.source.volume48
dc.source.issue9
dc.source.beginpage1980
dc.source.endpage1987
dc.source.countryEngland
rioxxterms.versionNAen_US
dc.contributor.trustauthorKunene, Victoria
dc.contributor.trustauthorFackrell, David
dc.contributor.trustauthorGriffiths, Ewen A
dc.contributor.departmentOncologyen_US
dc.contributor.departmentSurgeryen_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record